Researchers utilize FST-344 to investigate its high-affinity binding to myostatin and activin, thereby blocking their interaction with activin type II receptors and attenuating Smad2/3 activation. Pre-clinical observations in rodent, porcine, and nonhuman primate models indicate promotion of myofiber hypertrophy and hyperplasia, with enhanced skeletal muscle mass accrual in gene delivery systems.
This follistatin isoform supports detailed examination of TGF-β superfamily antagonism, muscle-bone coupling, and regenerative responses in fracture healing and metabolic stress paradigms.
Scientific Overview of FST-344 Applications
Pre-clinical models demonstrate FST-344’s sequestration of TGF-β family ligands:
- High-affinity binding to myostatin, preventing receptor activation and promoting skeletal muscle growth in transgenic porcine models. https://pubmed.ncbi.nlm.nih.gov/27787698/
- Neutralization of myostatin and activin to mitigate Smad signaling, leading to increased muscle mass and strength in rodent and nonhuman primate systems. https://pubmed.ncbi.nlm.nih.gov/19364964/
- Enhancement of muscle hypertrophy and hyperplasia through single-gene administration of myostatin inhibitors in long-term studies. https://pubmed.ncbi.nlm.nih.gov/18367517/
- Modulation of fracture callus size and bone volume in myostatin-deficient or follistatin-overexpressing models, supporting bone formation dynamics. https://pubmed.ncbi.nlm.nih.gov/11398858/
- Support for investigations into reduced adipose tissue inflammation and improved metabolic parameters in obesity-linked research contexts.
- Examination of TGF-β superfamily interactions for coordinated muscle and bone regeneration in multi-species injury models.
For broader insights into TGF-β superfamily antagonists, myostatin inhibition, and musculoskeletal signaling in pre-clinical research, refer to the Peptide Sciences or About Peptides sections.
Why Investigators Select National Science Labs FST-344
National Science Labs manufactures FST-344 under rigorous GMP-compliant protocols to deliver batch-to-batch consistency and reliability for pre-clinical experiments. Independent third-party testing verifies each lot for:
- Purity ≥99.9% by HPLC
- Structural identity confirmation via mass spectrometry
- Complete Certificate of Analysis (CoA) documentation provided per batch
For Research Use Only. This product is supplied exclusively for in vitro and in vivo pre-clinical research by qualified investigators. Statements about this peptide have not been evaluated by the FDA.
Initiate Your FST-344 Research Protocol
Source high-purity FST-344 from current limited batches to ensure optimal stability and performance in myostatin inhibition and musculoskeletal regulation studies.
